These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 35139240)

  • 21. Clinical efficacy and safety of chimeric antigen receptor T-cell therapy for mantle cell lymphoma with secondary central nervous system involvement.
    Ryan CE; Zon RL; Redd R; Fisher DC; Shouval R; Kumar A; Crombie JL; Sadrzadeh H; Kim AI; Nayak L; Chukwueke UN; Jacobson CA; Frigault MJ; Palomba ML; Armand P; Epstein-Peterson Z; Merryman RW
    Br J Haematol; 2023 Dec; 203(5):774-780. PubMed ID: 37584155
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Management of adverse events of CAR-T therapy].
    Arai Y
    Rinsho Ketsueki; 2023; 64(11):1465-1469. PubMed ID: 38072435
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Brain FDG-PET findings in chimeric antigen receptor T-cell therapy neurotoxicity for diffuse large B-cell lymphoma.
    Morbelli S; Gambella M; Raiola AM; Ghiggi C; Bauckneht M; Raimondo TD; Lapucci C; Sambuceti G; Inglese M; Angelucci E
    J Neuroimaging; 2023; 33(5):825-836. PubMed ID: 37291470
    [TBL] [Abstract][Full Text] [Related]  

  • 24. INSPIRED Symposium Part 3: Prevention and Management of Pediatric Chimeric Antigen Receptor T Cell-Associated Emergent Toxicities.
    McNerney KO; Hsieh EM; Shalabi H; Epperly R; Wolters PL; Hill JA; Gardner R; Talleur AC; Shah NN; Rossoff J
    Transplant Cell Ther; 2024 Jan; 30(1):38-55. PubMed ID: 37821079
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chimeric Antigen Receptor T Cell-Mediated Neurotoxicity in Nonhuman Primates.
    Taraseviciute A; Tkachev V; Ponce R; Turtle CJ; Snyder JM; Liggitt HD; Myerson D; Gonzalez-Cuyar L; Baldessari A; English C; Yu A; Zheng H; Furlan SN; Hunt DJ; Hoglund V; Finney O; Brakke H; Blazar BR; Berger C; Riddell SR; Gardner R; Kean LS; Jensen MC
    Cancer Discov; 2018 Jun; 8(6):750-763. PubMed ID: 29563103
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Management of adverse effects in CAR T-cell therapy].
    Goto H
    Rinsho Ketsueki; 2023; 64(9):1203-1212. PubMed ID: 37899201
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Building safety into CAR-T therapy.
    Peters DT; Savoldo B; Grover NS
    Hum Vaccin Immunother; 2023 Dec; 19(3):2275457. PubMed ID: 37968136
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hypophosphatemia Due to Increased Effector Cell Metabolic Activity Is Associated with Neurotoxicity Symptoms in CD19-Targeted CAR T-cell Therapy.
    Tang JP; Peters CW; Quiros C; Wang X; Klomhaus AM; Yamada RE; Timmerman JM; Moore TB; Nowicki TS
    Cancer Immunol Res; 2022 Dec; 10(12):1433-1440. PubMed ID: 36259217
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diabetes insipidus and Guillain-Barré-like syndrome following CAR-T cell therapy: a case report.
    Koch C; Fleischer J; Popov T; Frontzek K; Schreiner B; Roth P; Manz MG; Unseld S; Müller AMS; Russkamp NF
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36690387
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How I treat unique and difficult-to-manage cases of CAR T-cell therapy-associated neurotoxicity.
    Santomasso BD; Gust J; Perna F
    Blood; 2023 May; 141(20):2443-2451. PubMed ID: 36877916
    [TBL] [Abstract][Full Text] [Related]  

  • 31. How I treat refractory CRS and ICANS after CAR T-cell therapy.
    Jain MD; Smith M; Shah NN
    Blood; 2023 May; 141(20):2430-2442. PubMed ID: 36989488
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor inflammation-associated neurotoxicity.
    Mahdi J; Dietrich J; Straathof K; Roddie C; Scott BJ; Davidson TB; Prolo LM; Batchelor TT; Campen CJ; Davis KL; Gust J; Lim M; Majzner RG; Park JR; Partap S; Ramakrishna S; Richards R; Schultz L; Vitanza NA; Wang LD; Mackall CL; Monje M
    Nat Med; 2023 Apr; 29(4):803-810. PubMed ID: 37024595
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Case report: Rapid resolution of grade IV ICANS after first line intrathecal chemotherapy with methotrexate, cytarabine and dexamethasone.
    Katsin M; Shman T; Migas A; Lutskovich D; Serada Y; Khalankova Y; Kostina Y; Dubovik S
    Front Immunol; 2024; 15():1380451. PubMed ID: 38765003
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term survivorship care after CAR-T cell therapy.
    Puckrin R; Jamani K; Jimenez-Zepeda VH
    Eur J Haematol; 2024 Jan; 112(1):41-50. PubMed ID: 37767547
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patterns of neurotoxicity among patients receiving chimeric antigen receptor T-cell therapy: A single-centre cohort study.
    Sales C; Anderson MA; Kuznetsova V; Rosenfeld H; Malpas CB; Roos I; Dickinson M; Harrison S; Kalincik T
    Eur J Neurol; 2024 Mar; 31(3):e16174. PubMed ID: 38085272
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of diagnostic investigations in the management of CAR T-cell-associated neurotoxicity.
    Mauget M; Lemercier S; Quelven Q; Maamar A; Lhomme F; De Guibert S; Houot R; Manson G
    Blood Adv; 2024 May; 8(10):2491-2498. PubMed ID: 38501964
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review.
    Géraud A; Hueso T; Laparra A; Bige N; Ouali K; Cauquil C; Stoclin A; Danlos FX; Hollebecque A; Ribrag V; Gazzah A; Goldschmidt V; Baldini C; Suzzoni S; Bahleda R; Besse B; Barlesi F; Lambotte O; Massard C; Marabelle A; Castilla-Llorente C; Champiat S; Michot JM
    Eur J Cancer; 2024 Jul; 205():114075. PubMed ID: 38733717
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-world CAR-T findings for large B-cell lymphoma from a single institution experience.
    Lutfi F; Tun AM; Hoffmann M; Ahmed N
    Ann Palliat Med; 2024 May; 13(3):729-732. PubMed ID: 38644555
    [No Abstract]   [Full Text] [Related]  

  • 39. Chimeric Antigen Receptor T-Cell Therapy: What the Neuroradiologist Needs to Know.
    Valand HA; Huda F; Tu RK
    AJNR Am J Neuroradiol; 2019 May; 40(5):766-768. PubMed ID: 31048298
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potentially fatal complications of new systemic anticancer therapies: pearls and pitfalls in their initial management.
    Kovac MB; Seruga B
    Radiol Oncol; 2024 Jun; 58(2):170-178. PubMed ID: 38613842
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.